Currently, less well-studied but promising “emerging” CSF biomarkers of other disease processes have been reported [83], which are altered in individuals with symptomatic AD relative to controls, including neurogranin (Ng) [84,85,86], chitinase-3-like protein 1, also known as YKL-40 [87,88], synaptosomal-associated protein-25 (SNAP-25) [89], and visinin-like protein 1 (VILIP-1) [90,91]. The gene discussed is VSNL1; the disease is Alzheimer disease.